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ABSTRACT 
Glaucoma, the leading cause of irreversible blindness, is characterized by apoptotic death of 
retinal ganglion cells (RGCs). Elevated levels of endothelin1 (ET1), a potent vasoconstrictor, 
have been detected in the eyes and plasma of glaucoma patients. Increased endothelin 1 
causes retinal ischemia increased expression of nitric oxide synthase (NOS) isoforms and 
oxidative stress, which culminate into RGC apoptosis. Considering the vasodilating, and 
antioxidant properties of magnesium acetyltaurinate (MgAT) we hypothesized that it can prevent 
endothelin 1-induced vasospasm, improve retinal perfusion and reduce retinal oxidative stress 
by altering expression of 3 isoforms of NOS. Rats received single intravitreal injection of 
vehicle/ET1/ET1 with MgAT. Subsequently, histopathological examination of optic nerve were 
done to detect the extent of optic nerve damage. Immunochemical detection of NOS isoforms 
and estimation of NO and antioxidants was done in retina. It was observed that MgAT reduces 
retinal and optic nerve damage. This neuroprotective effect of MgAT was associated with 
reduced expression of NOS1 and 2, increased expression of NOS3 and reduced retinal 
oxidative stress. The results of this study were published in a Q1 journal and were presented in 
2 national and 3 international conferences. One student has completed her Master's research 
work and has been promoted to PhD. 
Further studies are needed to explore the full potential of MgAT as antiglaucoma agent and to 
develop its formulation. 
INTRODUCTION 
Glaucoma, an optic neuropathy, results from retinal ganglion cells (RGC) death and leads to 
progressive vision loss (Weinreb and Khaw 2004; Vecino and C. Sharma 2011). Population 
based studies have shown that one in 40 adults older than 40 years has glaucoma with vision 
loss, which equates to 60 million people worldwide. It is estimated that 8·4 million people 
worldwide have blindness due to glaucoma (Quigley 2011). Although elevation of IOP remains 
an important risk factor for glaucoma, not all glaucoma cases are associated with this risk factor. 
Approximately one third of all glaucoma cases have normal IOP, often within a range of 15 and 
20 mmHg, and this is known as normal tension glaucoma (NTG) (Buckley et al. 2002; R. 
Anderson 2011). Despite absence of significantly elevated IOP in all glaucoma cases, reduction 
of IOP remains the only treatment for glaucoma. There is adequate evidence to suggest that 
generalized vascular defect which produce alterations in both the ocular and systemic 
circulations such as decreased velocity of blood flow and increased resistance in retinal vessels 
are present in glaucoma (Ko et al. 2000; Buckley et al. 2002). Vascular dysregulation involving 
alterations in retinal perfusion are associated with ischemia-reperfusion induced damage. 
Furthermore, retinal ischemia induces oxidative stress and finally RGC apoptosis (Flamer J. et 
al. 2002). 
Recent evidence showed the association of glaucoma with elevated level of plasma endothelin-
1 (ET1). ET1 and Nitric Oxide (NO) regulate vascular tone locally. ET1 is a family of small 
potent vasoactive peptides. Due to its vasoconstrictive properties, it causes retinal ischemia; 
and has been recognized as an important target for the treatment of glaucomatous 
neuropathies. Both ET1 and NO are synthesized and released from ciliary process in the eye 
into the aqueous humor (Choritz et al. 2012). They are also produced by other cells involved in 
vascular diseases such as leukocytes, macrophages and smooth muscle cells (Luscher and 
Barton 2000). Excess of ET1 reduces optic nerve blood flow and promotes RGC death and 
decreased axon survival rates. ET1-induced RGC death also occurs due to reduced availability 
of growth factors caused by alterations in axonal transport (J. Lau et al. 2005). NO is a 
vasodilator and is believed to contribute to regulation of retinal perfusion and redox status (Dai 
et al. 2011). Its excessive production, however, increases nitrosative stress and is associated 
with altered expression of 3 isoforms of nitric oxide synthase (NOS). 
Magnesium has previously been shown to improve visual field in NTG patients (Korkmaz et al. 
2013). It is a physiological calcium blocker and can counteract the effects of ET1 by decreasing 
the vascular tone and increasing the retinal blood flow. This may involves altered expression of 
NOS and reduced retinal oxidative and nitrosative stress. Taurine is the most abundant amino 
acid in the ocular tissue and is a potent antioxidant. Hence, considering the vasodilating and 
antioxidant properties of magnesium acetyltaurinate, we hypothesized that it can prevent ET1-
induced loss of RGCs by reducing the retinal oxidative stress and altering the expression of 3 
isoforms of NOS. 
